| scholarly article | Q13442814 |
| P2093 | author name string | Xin Chen | |
| Diego F Calvisi | |||
| P2860 | cites work | Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines | Q73491986 |
| Epidemiology of hepatocellular carcinoma | Q73541726 | ||
| Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin | Q73773421 | ||
| Molecular pathogenesis of human hepatocellular carcinoma | Q74543031 | ||
| The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma | Q82176065 | ||
| On the role of notch1 and adult hepatocytes in murine intrahepatic cholangiocarcinoma development | Q86484678 | ||
| Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma | Q24556510 | ||
| Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors | Q24620075 | ||
| mTOR: from growth signal integration to cancer, diabetes and ageing | Q24633662 | ||
| Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach | Q24633776 | ||
| Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace | Q26858820 | ||
| Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies | Q27002547 | ||
| Aberrant Promoter Methylation Profiles of Tumor Suppressor Genes in Hepatocellular Carcinoma | Q27478395 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors | Q28214940 | ||
| Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma | Q28476545 | ||
| Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling | Q28513138 | ||
| Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines | Q28975767 | ||
| Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells | Q29617246 | ||
| Cancer stem cells: models and concepts | Q29620611 | ||
| The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice | Q29620765 | ||
| Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. | Q33180754 | ||
| Effect of genome size on AAV vector packaging | Q33730405 | ||
| Genetics of hepatocellular carcinoma | Q33998184 | ||
| Cancer gene discovery in hepatocellular carcinoma | Q34002120 | ||
| Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis | Q34062598 | ||
| Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas | Q34067016 | ||
| Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse | Q34144518 | ||
| Oncogene-specific formation of chemoresistant murine hepatic cancer stem cells | Q34233172 | ||
| Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. | Q34247788 | ||
| Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models | Q34266365 | ||
| MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer | Q34357796 | ||
| Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas | Q34380511 | ||
| Bmi1 is required for hepatic progenitor cell expansion and liver tumor development | Q34431278 | ||
| Hepatocellular carcinoma: an epidemiologic view | Q34528348 | ||
| Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. | Q34632966 | ||
| Investigation of oncogenic cooperation in simple liver-specific transgenic mouse models using noninvasive in vivo imaging. | Q34652500 | ||
| Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice | Q34661807 | ||
| Identification of rtl1, a retrotransposon-derived imprinted gene, as a novel driver of hepatocarcinogenesis | Q34672049 | ||
| Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. | Q34672477 | ||
| Self-complementary AAV vectors; advances and applications | Q34804660 | ||
| Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. | Q34821616 | ||
| Risk factors for cholangiocarcinoma | Q35074664 | ||
| Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages | Q35761435 | ||
| Aberrant CpG Island Hypermethylation Along Multistep Hepatocarcinogenesis | Q35792134 | ||
| The AAV vector toolkit: poised at the clinical crossroads | Q35876224 | ||
| Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma | Q35945177 | ||
| Distinct pathways of genomic progression to benign and malignant tumors of the liver. | Q35970966 | ||
| Cholangiocarcinomas can originate from hepatocytes in mice | Q36129118 | ||
| Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. | Q36336041 | ||
| Exploring genomic profiles of hepatocellular carcinoma. | Q36393332 | ||
| Contributions of human tumor xenografts to anticancer drug development | Q36439483 | ||
| Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials | Q36622291 | ||
| Molecular pathology of biliary tract cancers | Q36636828 | ||
| WNT/beta-catenin signaling in liver health and disease | Q36804161 | ||
| Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment | Q36900063 | ||
| Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis | Q37065772 | ||
| Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma | Q37177871 | ||
| Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma | Q37246194 | ||
| Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice | Q37303897 | ||
| Sorafenib for the treatment of unresectable hepatocellular carcinoma | Q37368694 | ||
| Role of alcohol in liver carcinogenesis | Q37456531 | ||
| Experimental mouse models for hepatocellular carcinoma research | Q37574072 | ||
| Mouse models of hepatocellular carcinoma | Q37696404 | ||
| AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application? | Q37825907 | ||
| Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis | Q37832697 | ||
| Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. | Q37857056 | ||
| Cholangiocarcinoma--controversies and challenges | Q37860916 | ||
| Genetics of hepatobiliary carcinogenesis | Q37871482 | ||
| Mouse models for liver cancer. | Q38083387 | ||
| Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. | Q39344238 | ||
| AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/ | Q39459058 | ||
| Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis | Q39771415 | ||
| A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver | Q39988585 | ||
| Hydroporation as the mechanism of hydrodynamic delivery | Q40014713 | ||
| Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties | Q40262786 | ||
| Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. | Q40314354 | ||
| The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. | Q40519865 | ||
| Efficient lentiviral transduction of liver requires cell cycling in vivo | Q40909303 | ||
| Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes | Q41626792 | ||
| Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system | Q41734970 | ||
| Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. | Q41832567 | ||
| Priming of hepatocytes enhances in vivo liver transduction with lentiviral vectors in adult mice | Q42424129 | ||
| In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. | Q44260023 | ||
| Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo | Q44845534 | ||
| Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma | Q45266560 | ||
| In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. | Q45280308 | ||
| High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice | Q45779177 | ||
| HBx gene of hepatitis B virus induces liver cancer in transgenic mice | Q45852802 | ||
| Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. | Q45861628 | ||
| Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1. | Q46232274 | ||
| Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer | Q46520772 | ||
| gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway | Q46853179 | ||
| A critical role for notch signaling in the formation of cholangiocellular carcinomas. | Q50945875 | ||
| A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. | Q51071233 | ||
| Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. | Q52221306 | ||
| Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. | Q53206297 | ||
| Hepatic Stem-like Phenotype and Interplay of Wnt/β-Catenin and Myc Signaling in Aggressive Childhood Liver Cancer | Q56762983 | ||
| Chronic Bile Duct Injury Associated with Fibrotic Matrix Microenvironment Provokes Cholangiocarcinoma in p53-Deficient Mice | Q58214837 | ||
| Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations | Q64379604 | ||
| c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis | Q71134011 | ||
| Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas | Q73107801 | ||
| Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma | Q73263453 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver cancer | Q623031 |
| P304 | page(s) | 912-923 | |
| P577 | publication date | 2014-01-28 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Hydrodynamic transfection for generation of novel mouse models for liver cancer research | |
| P478 | volume | 184 |
| Q38963997 | 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice |
| Q36778814 | A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma |
| Q48091492 | A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma |
| Q46519493 | A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis. |
| Q59790534 | A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment |
| Q39167037 | A shortcut for early macrophage recruitment into tumors by activated oncogenes |
| Q42468960 | Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade |
| Q91262178 | An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity in Mice |
| Q44620413 | An in vivo transfection system for inducible gene expression and gene silencing in murine hepatocytes |
| Q53911638 | An infernal cross-talk between oncogenic β-catenin and c-Met in hepatocellular carcinoma: Evidence from mouse modeling. |
| Q38428393 | Analysis of miRNA expression patterns in human and mouse hepatocellular carcinoma cells. |
| Q92922103 | Animal Modeling of Pediatric Liver Cancer |
| Q36372357 | Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375 |
| Q54217180 | Antiproliferative effect of urolithin A, the ellagic acid-derived colonic metabolite, on hepatocellular carcinoma HepG2.2.15 cells by targeting Lin28a/let-7a axis. |
| Q45059708 | Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. |
| Q64039535 | CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling |
| Q52427794 | CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice. |
| Q43088347 | Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development |
| Q91768548 | Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy |
| Q96817624 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management |
| Q92898129 | Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans |
| Q36560210 | Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. |
| Q35832927 | Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver |
| Q91656784 | Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma |
| Q36916485 | Comparison of liver oncogenic potential among human RAS isoforms |
| Q51396277 | Coordinated Activities of Multiple Myc-dependent and Myc-independent Biosynthetic Pathways in Hepatoblastoma. |
| Q47387974 | Cytoplasmic localization of the cell polarity factor Scribble supports liver tumor formation and tumor cell invasiveness. |
| Q47377422 | DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. |
| Q42339161 | Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma |
| Q46890816 | Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. |
| Q35907583 | Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background. |
| Q36922232 | Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. |
| Q37231321 | Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin |
| Q35740123 | Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer |
| Q100958823 | EAG1 enhances hepatocellular carcinoma proliferation by modulating SKP2 and metastasis through pseudopod formation |
| Q49952320 | Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. |
| Q64105137 | Emergence of the Dedifferentiated Phenotype in Hepatocyte-Derived Tumors in Mice: Roles of Oncogene-Induced Epigenetic Alterations |
| Q90458437 | Enhanced anti-tumor effect of liposomal Fasudil on hepatocellular carcinoma in vitro and in vivo |
| Q90383817 | Experimental Models to Define the Genetic Predisposition to Liver Cancer |
| Q64288110 | Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer |
| Q91873968 | Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma |
| Q58108213 | Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma |
| Q38614249 | Functional and genetic deconstruction of the cellular origin in liver cancer. |
| Q64053269 | Functional role of SGK3 in PI3K/Pten driven liver tumor development |
| Q92965169 | GREB1 induced by Wnt signaling promotes development of hepatoblastoma by suppressing TGFβ signaling |
| Q47838140 | Genetic Dissociation of Glycolysis and the TCA Cycle Affects Neither Normal nor Neoplastic Proliferation |
| Q37699310 | Gold nanoparticles delivered miR-375 for treatment of hepatocellular carcinoma |
| Q27302934 | Growth Arrest Specific 1 (Gas1) Gene Overexpression in Liver Reduces the In Vivo Progression of Murine Hepatocellular Carcinoma and Partially Restores Gene Expression Levels |
| Q92407464 | Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma |
| Q41549513 | Hepatic Loss of Borealin Impairs Postnatal Liver Development, Regeneration, and Hepatocarcinogenesis |
| Q36523963 | Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein |
| Q47270010 | Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice. |
| Q49603070 | Hippo cascade controls lineage commitment of liver tumors in mice and humans |
| Q35528356 | IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism |
| Q97643295 | Identifying strategies to target the metabolic flexibility of tumours |
| Q38827148 | Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans |
| Q57031525 | Integrative genomic analysis of mouse and human hepatocellular carcinoma |
| Q37525776 | Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans |
| Q41670848 | Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells |
| Q50176288 | Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway |
| Q61796853 | MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment |
| Q36125652 | MET is required for the recruitment of anti-tumoural neutrophils |
| Q42711666 | Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin. |
| Q38244965 | Molecular pathogenesis of intrahepatic cholangiocarcinoma |
| Q90448474 | Murine hepatoblast-derived liver tumors resembling human combined hepatocellular-cholangiocarcinoma with stem cell features |
| Q89702057 | NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis |
| Q55311926 | Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. |
| Q88616673 | Novel Genetic Activation Screening in Liver Repopulation and Cancer: Now CRISPR Than Ever! |
| Q39001915 | Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma |
| Q89386653 | Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma |
| Q89531796 | Oncogene-dependent function of BRG1 in hepatocarcinogenesis |
| Q94521075 | Oncogenic driver genes and tumor microenvironment determine the type of liver cancer |
| Q36501683 | Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice |
| Q59127582 | Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice |
| Q64994470 | Paeonol-mediated apoptosis of hepatocellular carcinoma cells by NF-κB pathway. |
| Q33907588 | Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. |
| Q45870005 | Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. |
| Q34044638 | Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. |
| Q48102709 | Quantitative self-assembly prediction yields targeted nanomedicines. |
| Q40078177 | Ribosomopathy-like properties of murine and human cancers |
| Q35273519 | SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice |
| Q36190850 | Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy |
| Q52367078 | Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET. |
| Q41957741 | Single tumor-initiating cells evade immune clearance by recruiting type II macrophages |
| Q91833695 | TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma |
| Q46828939 | Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice |
| Q38972723 | The application of antitumor drug-targeting models on liver cancer |
| Q91812871 | The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans |
| Q91974758 | The role of bone marrow-derived cells in the origin of liver cancer revealed by single-cell sequencing |
| Q35015462 | Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor. |
| Q38556534 | Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy |
| Q90632828 | Validation of Hepatocellular Carcinoma Experimental Models for TGF-β Promoting Tumor Progression |
| Q36900941 | [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice |
| Q90726562 | p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression |
| Q51761242 | p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. |
| Q92665666 | β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma |
| Q46735091 | β-Catenin Deficiency in Hepatocytes Aggravates Hepatocarcinogenesis Driven by Oncogenic β-Catenin and MET. |
Search more.